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In Kampala, Uganda, in 2001, hepatitis C virus anti-
bodies were found in 27 (4%) of 603 children and in 62
(12%) of 525 of their mothers. However, only ≈10% of pos-
itive results were confirmed by reverse transcription–PCR,
which suggests frequent false-positive results or viral clear-
ance. All sequenced types were genotype 4.
T
he prevalence of hepatitis C virus (HCV) infection in
sub-Saharan African populations is an estimated 3%,
with modest regional variation (1). The true prevalence
may be lower because some positive HCV ELISA results
may be due to cross-reactivity, and the reliability of recom-
binant immunoblot assay (RIBA) as a confirmatory assay
is unclear (2,3). Few studies have confirmed antibody-pos-
itive results by molecular methods, and data on HCVgeno-
types in Africans are limited.
In Uganda, 2 studies showed a low HCV seropreva-
lence (2,4), but neither examined samples for viral RNA.
In 2001, we conducted a survey of Ugandan children with
sickle cell disease and their mothers and found that human
herpesvirus 8 infection was associated with transfusion in
these children (5). Children with sickle cell anemia receive
frequent injections during their care, and transfusions are
frequently required for anemia. We therefore assumed that
our population would be at increased risk for HCV infec-
tion. We tested for HCV antibodies and, on antibody-posi-
tive samples, sought HCV RNA to confirm antibody
reactivity. For RNA-positive samples, we identified geno-
types by sequencing and phylogenetic analysis.
The Study
In 2001, we enrolled 603 children (1–16 years of age)
attending the Sickle Cell Clinic at Mulago Hospital,
Kampala, in our study. By design, approximately half of
the children had a history of blood transfusion. When
available, the mothers of these children were also enrolled.
Participants provided standardized information and blood
samples. Plasma and buffy coats were immediately pre-
pared and frozen at −80°C until testing.
Plasma specimens were tested by using an ELISA for
HCV antibodies to recombinant antigens c22, c200, and
NS5B (ELISA-3.0, Ortho-Clinical Diagnostics, Raritan,
NJ, USA) according to the manufacturer’s instructions. To
conserve samples we did not confirm positive results by
RIBAbut instead tested for virus in plasma by using a real-
time reverse transcription (RT)–PCR assay for HCV RNA
developed in our laboratory. This quantitative assay ampli-
fied a conserved 155-nucleotide target sequence within the
HCV 5′ untranslated region and had an absolute sensitivi-
ty of 9 IU/mLof viral load (43 copies/mL). Total RNAwas
extracted from 140 µL plasma by using the Qiagen Viral
RNA Mini kit (Qiagen, Valencia, CA, USA). RT-PCR was
performed in a Thermo Hybaid MBS 0.2S (Fisher
Scientific International, Hampton, NH, USA) in triplicate
reactions that used 10 µL RNA per reaction. After cDNA
synthesis, quantitative PCR was performed by using an
ABI Prism 7700 or 7900 Sequence Detection System
(Applied BioSystems, Foster City, CA, USA). HCV
RNA–positive specimens were further characterized by
sequencing parts of the Core/E1 and NS5B regions.
Briefly, purified RNA was used to generate cDNA by
reverse transcription. Nested PCR was performed with sets
of published PCR primers to amplify DNA from Core/E1
or NS5B regions (6,7). The amplification products were
separated in an agarose gel and purified by using the
Promega DNA purification kit (Promega, Madison, WI,
USA). The BigDye Terminator kit (Applied BioSystems)
was used to prepare products for sequencing in an Applied
BioSystems 310 automated sequencer.
Separate alignments were generated for the NS5B and
Core/E1 regions, each including sequences from our sam-
ples and genotype 1 to 6 reference sequences obtained
from GenBank (7). Additional genotype 4 reference
sequences used in the analysis are listed in the Figure.
These sequences were aligned in ClustalX (version 1.81,
Plate-Forme de Bio-Informatique, Illkirch, France) by
using the ClustalW (version 1.6, Plate-Forme de Bio-
Informatique) matrix and edited in GeneDoc version 2.6
(www.psc.edu/biomed/genedoc). In Mega version 2.1
(www.megasoftware.net), the Clustal alignments for
Core/E1 and NS5B were used to generate neighbor-join-
ing trees by using the Kimura 2-parameter plus Γ distribu-
tion (K80+Γ) distance model. Free parameters were
reduced to the K80 model, and α values were determined
by using a maximum likelihood approach in PAUP*4.0
(Sinauer Associates, Inc. Publishers, Sunderland, MA,
USA).
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Kampala, UgandaOf 603 children (median age 6.8 years, interquartile
range 3.9–10.9 years), 27 (4%) were HCV antibody posi-
tive. No significant trends were found between HCV status
and demographic (age, sex, tribe) or household
(urban/rural location, water supply, room density) vari-
ables. Three (5%) of 61 children born to HCV-seropositive
mothers were HCV seropositive, compared with 16 (3%)
of 456 children born to seronegative mothers (p = 0.58).
Eleven (3%) of 322 children with a history of transfusion
(mean 1.5 transfusions, range 1–10) were HCV seroposi-
tive, compared with 12 (5%) of 245 children with no his-
tory of transfusion (p = 0.38). Prevalences in children with
(2%) and without (4%) history of scarification were also
similar (p = 0.38).
Using RT-PCR to test for HCV RNA, we examined 58
samples from children: all 27 samples with antibody-posi-
tive results, 11 with high-negative (near the positive cut-
off) results, 10 with negative results from children with a
history of frequent transfusions, and 10 with low-negative
results from children with no history of transfusion. Only
3 samples, all from seropositive children (ages 6, 7, and 13
years), had positive results by RT-PCR, and viral RNAlev-
els in these samples were 2.3×103, 2.8×104, and 3.8×106
HCV IU/mL plasma.
Of 525 serum samples available from mothers, 62
(12%) were antibody positive. We sought HCV RNAin all
62 mothers with positive ELISA results and in 20 mothers
with high-negative results. Five (8%) antibody-positive
mothers (ages 28, 30, 38, 39, and 42 years) had RNA-pos-
itive samples. Viral levels varied from 6.6×103 to 5.7×105
HCV IU/mL (median 8.1×104). All HCV-seronegative
mothers (median age 32.3 years, mean 33.2 years, standard
deviation 7.6) were RNA negative.
We amplified samples for sequencing from 5 mothers
and 1 child and obtained Core/E1 sequences for all 6 sam-
ples and NS5B sequences for 3 samples. None of the
sequences was identical to any other or to any sequence in
GenBank. Phylogenetic analysis of both the NS5B and
Core/E1 regions showed that all viruses amplified clus-
tered within genotype 4 (Figures 1 and 2). In the Core/E1
phylogeny (Figure 2), 2 clusters of HCV strains and 1 out-
lier (UG1) appeared. Each of the NS5B sequences
obtained (Figure 1) was from a different Core/E1 group
and they did not cluster. Sequences from this study have
been deposited in GenBank (accession nos. AY577578–
AY577586).
Conclusions
We found HCV infection to be uncommon in Uganda,
consistent with reports from other Ugandan studies. This
cohort of patients with sickle cell disease had frequent
blood transfusions, but only 4% of the children were HCV
positive by ELISA. Of the seropositive children, only 11%
had HCV RNA detectable by RT-PCR. Seropositivity in
their mothers was higher, 12%, but only 8% of the seropos-
itive women had positive RT-PCR results. If we assume
that untested seronegative patients were not viremic, the
overall prevalence of HCV RNAwas 0.5% in children and
1% in mothers.
These results might indicate that false-positive ELISA
results for HCV are frequent. False-positive results could
be due to nonspecific antibody binding or to cross-reactiv-
ity with other tropical pathogens, e.g., flaviviruses found in
Africa (2,3). Alternatively, perhaps true antibody-positive
participants did not have positive RT-PCR results because
they had cleared HCV viremia; however, in the industrial-
ized world, most antibody-positive persons have persistent
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Figure 1. Estimated phylogenies of hepatitis C virus genotype 4;
NS5B phylogenetic analysis based on 350 bp of NS5B nucleotide
sequence. Ugandan sequences determined in this study are high-
lighted in black. Numerical values (presented when >60%) repre-
sent the statistical support for the tree topology as determined by
1,000 bootstrap replicates. Reference sequences for genotypes
1–3, 5, and 6 (7) were included in both analyses and retained as
the outgroup. Accession numbers are provided in the text.viremia. We did not confirm ELISA positivity with RIBA
because, in Africa, few HCV ELISA-positive samples are
confirmed by RIBA (3,8).
Our RT-PCR results confirm that HCV is present in
Uganda, albeit at a low prevalence. How HCV is transmit-
ted in sub-Saharan Africa is not known. We did not find
correlations between infection in children and either
seropositivity or viremia in their mothers. We expected to
see iatrogenic transmission (1,8) because the children in
this study all had sickle cell disease and more than half had
had blood transfusions, and many had had multiple trans-
fusions. Most children would have also had potential expo-
sure to HCV from contaminated needles used during the
course of their medical care or blades used in scarification
by traditional healers (9). However, despite these potential
exposures, documented HCV infections were uncommon.
Most HCV isolates can be classified into 6 major geno-
types on the basis of sequence data from the NS5B, core,
and E1 genomic regions. In this study, as in others (8),
multiple sets of primers were needed to amplify these
regions because different primer sets worked for different
samples, which reflects the diversity of HCV. Our HCV
Core/E1 tree showed 3 clusters. Neither the Core/E1 nor
NS5B sequences in Uganda clustered closely with geno-
type 4 sequences reported from other areas (Figures 1 and
2). Because the number of sequences was limited, we have
not assigned subtypes to our newly described variants.
In sub-Saharan Africa, genotype frequencies vary by
location (10). We found only genotype 4 in Uganda.
Genotype 4 has been found in the west-central nations of
Africa (Nigeria, Cameroon, Gabon, and Central African
Republic), but it also occurs in Tanzania (11). Phylogenetic
analysis shows that types 1 and 4 share a common ances-
tor (12). Ndjomou et al. (13) noted that genotypes 1 and 4
in Cameroon have considerable genetic diversity and sug-
gested that these types may have arisen there. They postu-
late that genotype 4 spread east into central Africa. Our
detection of HCV genotype 4 in Uganda is consistent with
their hypothesis, but we do not know the direction of
spread. Type 4 is also found in Egypt, where its epidemic
distribution is attributed to widespread iatrogenic trans-
mission during schistosomiasis eradication campaigns
from 1960 to 1980 (in which needles for injecting potassi-
um antimony tartrate were reused after rudimentary clean-
ing) (7,14), and in the Arabian Peninsula (15). For many
centuries, Arab traders have had extensive contact with
African populations of the Nile watershed region, includ-
ing Uganda, which provides routes for genotype 4 to
spread between East Africa and the Middle East.
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